You are here

MULTIFUNCTIONAL SIRNA NANOPARTICLES FOR AML THERAPY

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N43CO201000051
Agency Tracking Number: N43CO201000051
Amount: $200,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PHS2010-1
Timeline
Solicitation Year: 2010
Award Year: 2010
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1109 MILLCREEK LN
COLUMBUS, OH 43220-4949
United States
DUNS: 167239057
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 Xiaojuan Yang
Business Contact
Phone: (614) 442-1231
Email: lienyu4675@yahoo.com
Research Institution
N/A
Abstract

This project will investigate transferrin (Tf) conjugated fluorescent nanoparticles loaded with an siRNA, LOR-1284, as a theranostic agent for acute myelogenous leukemia (AML). LOR-1284, a siRNA targeting the R2 subunit of ribonucleotide reductase (RNR), is a promising agent for overcoming RNR-mediated drug resistance in AML. The nanoparticles are designed to facilitate LOR-1284 delivery to AML cells (for therapy) while enabling easy detection of delivery efficiency to the AML cells in leukemia patients (for diagnosis). A novel microfluidic method has been developed for nanoparticle synthesis. This project will be carried out by a multidisciplinary team of investigators at NIL and at The Ohio State University.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government